Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept.

Minerva chirurgica

VAN DEN Heuvel B, Peeters M, Hendlisz A, VAN DEN Eynde M, Machiels G, Dero I, Geboes K, DE Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraten E, VAN Laethem JL, Lybaert W, Holbrechts S, Rolfo C.
PMID: 26771252
Minerva Chir. 2016 Jan 15; Epub 2016 Jan 15.

BACKGROUND: The aim of this study is to investigate the role of Octreotide LAR in secondary prevention in patients with chemotherapy-induced diarrhea.METHODS: In this study, patients experiencing CID ≥ grade 2 received 30 mg long-acting octreotide as a monthly...

Cite
VAN DEN Heuvel B, Peeters M, Hendlisz A, et al. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva Chir. 2016;
VAN DEN Heuvel, B., Peeters, M., Hendlisz, A., VAN DEN Eynde, M., Machiels, G., Dero, I., Geboes, K., DE Man, M., Hendrickx, K., Delaunoit, T., Monsaert, E., Vanderstraten, E., VAN Laethem, J. L., Lybaert, W., Holbrechts, S., & Rolfo, C. (2016). Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva chirurgica, .
VAN DEN Heuvel, Bert, et al. "Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept." Minerva chirurgica vol. (2016).
VAN DEN Heuvel B, Peeters M, Hendlisz A, VAN DEN Eynde M, Machiels G, Dero I, Geboes K, DE Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraten E, VAN Laethem JL, Lybaert W, Holbrechts S, Rolfo C. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva Chir. 2016 Jan 15; Epub 2016 Jan 15. PMID: 26771252.
Copy Download .nbib Format: NLM
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

Clinical colorectal cancer

Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F.
PMID: 34404621
Clin Colorectal Cancer. 2021 Jul 24; doi: 10.1016/j.clcc.2021.07.006. Epub 2021 Jul 24.

BACKGROUND: Regorafenib is a standard treatment for refractory metastatic colorectal cancer (mCRC). In view of the toxicity burden, significant research efforts have been made to increase the therapeutic ratio of this multikinase inhibitor. Predictive factors for treatment-related adverse events...

Cite
Vandeputte C, Bregni G, Gkolfakis P, et al. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021;doi: 10.1016/j.clcc.2021.07.006.
Vandeputte, C., Bregni, G., Gkolfakis, P., Guiot, T., Pretta, A., Kehagias, P., Senti, C., Reina, E. A., Van Bogaert, C., Deleporte, A., Geboes, K., Delaunoit, T., Demolin, G., Peeters, M., D'Hondt, L., Janssens, J., Carrasco, J., Holbrechts, S., Goeminne, J. C., Vergauwe, P., Van Laethem, J. L., Flamen, P., Hendlisz, A., & Sclafani, F. (2021). Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clinical colorectal cancer, . https://doi.org/10.1016/j.clcc.2021.07.006
Vandeputte, Caroline, et al. "Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial." Clinical colorectal cancer vol. (2021). doi: https://doi.org/10.1016/j.clcc.2021.07.006
Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021 Jul 24; doi: 10.1016/j.clcc.2021.07.006. Epub 2021 Jul 24. PMID: 34404621.
Copy Download .nbib Format: NLM
[The beautiful adventure of Télévie].

Bulletin et memoires de l'Academie royale de medecine de Belgique

de Launoit JP.
PMID: 15244346
Bull Mem Acad R Med Belg. 2003;158(10):400-4.

No abstract available.

Cite
de Launoit JP. La belle aventure du Télévie. [The beautiful adventure of Télévie]. Bull Mem Acad R Med Belg. 2003;158(10):400-4
de Launoit, J. P. (2003). La belle aventure du Télévie. [The beautiful adventure of Télévie]. Bulletin et memoires de l'Academie royale de medecine de Belgique, 158(10), 400-4.
de Launoit, J P. "La belle aventure du Télévie." [The beautiful adventure of Télévie]. Bulletin et memoires de l'Academie royale de medecine de Belgique vol. 158,10 (2003): 400-4.
de Launoit JP. La belle aventure du Télévie. [The beautiful adventure of Télévie]. Bull Mem Acad R Med Belg. 2003;158(10):400-4. French. PMID: 15244346.
Copy Download .nbib Format: NLM
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Annals of oncology : official journal of the European Society for Medical Oncology

, Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, MatysiakBudnik T, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, GuenterDerigs H, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Labianca R, Colucci G, Amadori D, Mini E, Falcone A, Boni C, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Tabernero J, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, ValladaresAyerbes M, FeliuBatlle J, Gil S, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, CireraNogueras L, Merino B, Castro CG, de Prado PM, PijaumePericay C, ConstenlaFigueiras M, Jordan I, GomeReina MJ, Garcia AL, Garcia-Ramos AA, Cervantes A, Martos CF, MarcuelloGaspar E, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, GuillotMorales M, LlanosMuñoz M, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, HernandezBusquier I, Ruiz TC, LacastaMuñoa A, Aliguer M, Ortiz de Taranco AV, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, GalanBrotons A, AlbiolRodriguez S, Martinez JA, Ruiz LC, CentellesRuiz M, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L.
PMID: 25814651
Ann Oncol. 2015 Apr;26(4):822-825. doi: 10.1093/annonc/mdv070.

No abstract available.

Cite
, Thaler J, Greil R, et al. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol. 2015;26(4):822-825doi: 10.1093/annonc/mdv070.
, Thaler, J., Greil, R., Gaenzer, J., Eisterer, W., Tschmelitsch, J., Samonigg, H., Zabernigg, A., Schmid, F., Steger, G., Steinacher, R., Andel, J., Lang, A., Függer, R., Hofbauer, F., Woell, E., Geissler, D., Lenauer, A., Prager, M., Van Laethem, J. L., Van Cutsem, E., D'Haens, G., Demolin, G., Kerger, J., Deboever, G., Ghillebert, G., Polus, M., Van Cutsem, E., RezaieKalantari, H., Delaunoit, T., Goeminne, J. C., Peeters, M., Vergauwe, P., Houbiers, G., Humblet, Y., Janssens, J., Schrijvers, D., Vanderstraeten, E., Van Laethem, J. L., Vermorken, J., Van Daele, D., Ferrante, M., Forget, F., Hendlisz, A., Yilmaz, M., Nielsen, S. E., Vestermark, L., Larsen, J., Ychou, M., Zawadi, A., Zawadi, M. A., Bouche, O., Mineur, L., Bennouna-Louridi, J., Dourthe, L. M., Ychou, M., Boucher, E., Taieb, J., Pezet, D., Desseigne, F., Ducreux, M., Texereau, P., Miglianico, L., Rougier, P., Fratte, S., Levache, C. B., Merrouche, Y., Ellis, S., Locher, C., Ramee, J. F., Garnier, C., Viret, F., Chauffert, B., Cojean-Zelek, I., Michel, P., Lecaille, C., Borel, C., Seitz, J. F., Smith, D., Lombard-Bohas, C., Andre, T., Gornet, J. M., Fein, F., Coulon-Sfairi, M. A., Kaminsky, M. C., Lagasse, J. P., Luet, D., Etienne, P. L., Gasmi, M., Vanoli, A., Nguyen, S., Aparicio, T., Perrier, H., Stremsdoerfer, N., Laplaige, P., Arsene, D., Auby, D., Bedenne, L., Coriat, R., Denis, B., Geoffroy, P., Piot, G., Becouarn, Y., Bordes, G., Deplanque, G., Dupuis, O., Fruge, F., Guimbaud, R., Lecomte, T., Lledo, G., Sobhani, I., Asnacios, A., Azzedine, A., Desauw, C., Galais, M. P., Gargot, D., Lam, Y. H., Abakar-Mahamat, A., Berdah, J. F., Catteau, S., Clavero-Fabri, M. C., Codoul, J. F., Legoux, J. L., Goldfain, D., Guichard, P., Verge, D. P., Provencal, J., Vedrenne, B., Brezault-Bonnet, C., Cleau, D., Desir, J. P., Fallik, D., Garcia, B., Gaspard, M. H., Genet, D., Hartwig, J., Krummel, Y., MatysiakBudnik, T., Palascak-Juif, V., Randrianarivelo, H., Rinaldi, Y., Aleba, A., Darut-Jouve, A., de Gramont, A., Hamon, H., Wendehenne, F., Matzdorff, A., Stahl, M. K., Schepp, W., Burk, M., Mueller, L., Folprecht, G., Geissler, M., Mantovani-Loeffler, L., Hoehler, T., Asperger, W., Kroening, H., von Weikersthal, L. F., Fuxius, S., Groschek, M., Meiler, J., Trarbach, T., Rauh, J., Ziegenhagen, N., Kretzschmar, A., Graeven, U., Nusch, A., von Wichert, G., Hofheinz, R. D., Kleber, G., Schmidt, K. H., Vehling-Kaiser, U., Baum, C., Schuette, J., Haag, G. M., Holtkamp, W., Potenberg, J., Reiber, T., Schliesser, G., Schmoll, H. J., Schneider-Kappus, W., Abenhardt, W., Denzlinger, C., Henning, J., Marxsen, B., GuenterDerigs, H., Lambertz, H., Becker-Boost, I., Caca, K., Constantin, C., Decker, T., Eschenburg, H., Gabius, S., Hebart, H., Hoffmeister, A., Horst, H. A., Kremers, S., Leithaeuser, M., Mueller, S., Wagner, S., Daum, S., Schlegel, F., Stauch, M., Heinemann, V., Labianca, R., Colucci, G., Amadori, D., Mini, E., Falcone, A., Boni, C., Maiello, E., Latini, L., Zaniboni, A., Amadori, D., Aprile, G., Barni, S., Mattioli, R., Martoni, A., Passalacqua, R., Nicolini, M., Pasquini, E., Rabbi, C., Aitini, E., Ravaioli, A., Barone, C., Biasco, G., Tamberi, S., Gambi, A., Verusio, C., Marzola, M., Lelli, G., Boni, C., Cascinu, S., Bidoli, P., Vaghi, M., Cruciani, G., Di Costanzo, F., Sobrero, A., Mini, E., Petrioli, R., Aglietta, M., Alabiso, O., Capuzzo, F., Falcone, A., Corsi, D. C., Labianca, R., Salvagni, S., Chiara, S., Ferraù, F., Giuliani, F., Lonardi, S., Gebbia, N., Mantovani, G., Sanches, E., Sanches, E., Mellidez, J. C., Santos, P., Freire, J., Sarmento, C., Costa, L., Pinto, A. M., Barroso, S., Santo, J. E., Guedes, F., Monteiro, A., Sa, A., Furtado, I., Tabernero, J., Salazar, R., Aguilar, E. A., Herrero, F. R., Tabernero, J., Valera, J. S., ValladaresAyerbes, M., FeliuBatlle, J., Gil, S., Garcia-Giron, C., Vivanco, G. L., Salvia, A. S., Orduña, V. A., Garcia, R. V., Gallego, J., Sureda, B. M., Remon, J., Safont Aguilera, M. J., CireraNogueras, L., Merino, B., Castro, C. G., de Prado, P. M., PijaumePericay, C., ConstenlaFigueiras, M., Jordan, I., GomeReina, M. J., Garcia, A. L., Garcia-Ramos, A. A., Cervantes, A., Martos, C. F., MarcuelloGaspar, E., Montero, I. C., Emperador, P. E., Carbonero, A. L., Castillo, M. G., Garcia, T. G., Lopez, J. G., Flores, E. G., GuillotMorales, M., LlanosMuñoz, M., Martín, A. L., Maurel, J., Camara, J. C., Garcia, R. D., Salgado, M., HernandezBusquier, I., Ruiz, T. C., LacastaMuñoa, A., Aliguer, M., Ortiz de Taranco, A. V., Ureña, M. M., Gaspa, F. L., Ponce, J. J., Roig, C. B., Jimenez, P. V., GalanBrotons, A., AlbiolRodriguez, S., Martinez, J. A., Ruiz, L. C., CentellesRuiz, M., Bridgewater, J., Glynne-Jones, R., Tahir, S., Hickish, T., Cassidy, J., & Samuel, L. (2015). Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Annals of oncology : official journal of the European Society for Medical Oncology, 26(4), 822-825. https://doi.org/10.1093/annonc/mdv070
, et al. "Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset." Annals of oncology : official journal of the European Society for Medical Oncology vol. 26,4 (2015): 822-825. doi: https://doi.org/10.1093/annonc/mdv070
, Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, MatysiakBudnik T, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, GuenterDerigs H, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Labianca R, Colucci G, Amadori D, Mini E, Falcone A, Boni C, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Tabernero J, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, ValladaresAyerbes M, FeliuBatlle J, Gil S, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, CireraNogueras L, Merino B, Castro CG, de Prado PM, PijaumePericay C, ConstenlaFigueiras M, Jordan I, GomeReina MJ, Garcia AL, Garcia-Ramos AA, Cervantes A, Martos CF, MarcuelloGaspar E, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, GuillotMorales M, LlanosMuñoz M, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, HernandezBusquier I, Ruiz TC, LacastaMuñoa A, Aliguer M, Ortiz de Taranco AV, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, GalanBrotons A, AlbiolRodriguez S, Martinez JA, Ruiz LC, CentellesRuiz M, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol. 2015 Apr;26(4):822-825. doi: 10.1093/annonc/mdv070. PMID: 25814651.
Copy Download .nbib Format: NLM
Management of esophageal superficial tumors: non take away approaches.

Acta gastro-enterologica Belgica

Delaunoit T.
PMID: 22567740
Acta Gastroenterol Belg. 2012 Mar;75(1):5-8.

Development of screening programs in patients with high risk of developing esophageal cancer, as well as recent advances in diagnostic endoscopic techniques, have allowed clinicians to improve early detection of esophageal malignant tumors. Surgical resection, although currently considered as...

Cite
Delaunoit T. Management of esophageal superficial tumors: non take away approaches. Acta Gastroenterol Belg. 2012;75(1):5-8
Delaunoit, T. (2012). Management of esophageal superficial tumors: non take away approaches. Acta gastro-enterologica Belgica, 75(1), 5-8.
Delaunoit, Thierry. "Management of esophageal superficial tumors: non take away approaches." Acta gastro-enterologica Belgica vol. 75,1 (2012): 5-8.
Delaunoit T. Management of esophageal superficial tumors: non take away approaches. Acta Gastroenterol Belg. 2012 Mar;75(1):5-8. PMID: 22567740.
Copy Download .nbib Format: NLM
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

Clinical colorectal cancer

Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F.
PMID: 34404621
Clin Colorectal Cancer. 2021 Dec;20(4):326-333. doi: 10.1016/j.clcc.2021.07.006. Epub 2021 Jul 24.

BACKGROUND: Regorafenib is a standard treatment for refractory metastatic colorectal cancer (mCRC). In view of the toxicity burden, significant research efforts have been made to increase the therapeutic ratio of this multikinase inhibitor. Predictive factors for treatment-related adverse events...

Cite
Vandeputte C, Bregni G, Gkolfakis P, et al. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021;20(4):326-333doi: 10.1016/j.clcc.2021.07.006.
Vandeputte, C., Bregni, G., Gkolfakis, P., Guiot, T., Pretta, A., Kehagias, P., Senti, C., Reina, E. A., Van Bogaert, C., Deleporte, A., Geboes, K., Delaunoit, T., Demolin, G., Peeters, M., D'Hondt, L., Janssens, J., Carrasco, J., Holbrechts, S., Goeminne, J. C., Vergauwe, P., Van Laethem, J. L., Flamen, P., Hendlisz, A., & Sclafani, F. (2021). Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clinical colorectal cancer, 20(4), 326-333. https://doi.org/10.1016/j.clcc.2021.07.006
Vandeputte, Caroline, et al. "Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial." Clinical colorectal cancer vol. 20,4 (2021): 326-333. doi: https://doi.org/10.1016/j.clcc.2021.07.006
Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clin Colorectal Cancer. 2021 Dec;20(4):326-333. doi: 10.1016/j.clcc.2021.07.006. Epub 2021 Jul 24. PMID: 34404621.
Copy Download .nbib Format: NLM
Latest developments and emerging treatment options in the management of stomach cancer.

Cancer management and research

Delaunoit T.
PMID: 21792334
Cancer Manag Res. 2011;3:257-66. doi: 10.2147/CMR.S12713. Epub 2011 Jul 13.

Gastric cancer remains a significant health burden worldwide. Most of these malignancies are diagnosed at an advanced stage and are associated with a grim prognosis. Complete removal of macroscopic and microscopic tumor masses along with regional lymphnodes (R0 surgical...

Cite
Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res. 2011;3:257-66doi: 10.2147/CMR.S12713.
Delaunoit, T. (2011). Latest developments and emerging treatment options in the management of stomach cancer. Cancer management and research, 3257-66. https://doi.org/10.2147/CMR.S12713
Delaunoit, Thierry. "Latest developments and emerging treatment options in the management of stomach cancer." Cancer management and research vol. 3 (2011): 257-66. doi: https://doi.org/10.2147/CMR.S12713
Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res. 2011;3:257-66. doi: 10.2147/CMR.S12713. Epub 2011 Jul 13. PMID: 21792334; PMCID: PMC3139486.
Copy Download .nbib Format: NLM
Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma.

ISRN hepatology

Ouaguia L, Morales O, Mrizak D, Ghazal K, Boleslawski E, Auriault C, Pancré V, de Launoit Y, Conti F, Delhem N.
PMID: 27335834
ISRN Hepatol. 2013 Oct 23;2013:928485. doi: 10.1155/2013/928485. eCollection 2013.

Hepatitis C virus (HCV) is an important causative agent of liver disease, but factors that determine the resolution or progression of infection are poorly understood. In this study, we suggested that existence of immunosuppressive mechanisms, supported by regulatory T...

Cite
Ouaguia L, Morales O, Mrizak D, et al. Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma. ISRN Hepatol. 2013;2013:928485doi: 10.1155/2013/928485.
Ouaguia, L., Morales, O., Mrizak, D., Ghazal, K., Boleslawski, E., Auriault, C., Pancré, V., de Launoit, Y., Conti, F., & Delhem, N. (2013). Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma. ISRN hepatology, 2013928485. https://doi.org/10.1155/2013/928485
Ouaguia, Laurissa, et al. "Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma." ISRN hepatology vol. 2013 (2013): 928485. doi: https://doi.org/10.1155/2013/928485
Ouaguia L, Morales O, Mrizak D, Ghazal K, Boleslawski E, Auriault C, Pancré V, de Launoit Y, Conti F, Delhem N. Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma. ISRN Hepatol. 2013 Oct 23;2013:928485. doi: 10.1155/2013/928485. eCollection 2013. PMID: 27335834; PMCID: PMC4890904.
Copy Download .nbib Format: NLM
Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Oncotarget

Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A.
PMID: 29707145
Oncotarget. 2018 Apr 03;9(25):17756-17769. doi: 10.18632/oncotarget.24879. eCollection 2018 Apr 03.

Predictive biomarkers are eagerly awaited in advanced colorectal cancer (aCRC). Targeted sequencing performed on tumor and baseline plasma samples in 20 patients with aCRC treated with regorafenib identified 89 tumor-specific mutations of which ≥50% are also present in baseline...

Cite
Vandeputte C, Kehagias P, El Housni H, et al. Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget. 2018;9(25):17756-17769doi: 10.18632/oncotarget.24879.
Vandeputte, C., Kehagias, P., El Housni, H., Ameye, L., Laes, J. F., Desmedt, C., Sotiriou, C., Deleporte, A., Puleo, F., Geboes, K., Delaunoit, T., Demolin, G., Peeters, M., D'Hondt, L., Janssens, J., Carrasco, J., Marechal, R., Galdon, M. G., Heimann, P., Paesmans, M., Flamen, P., & Hendlisz, A. (2018). Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget, 9(25), 17756-17769. https://doi.org/10.18632/oncotarget.24879
Vandeputte, Caroline, et al. "Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor." Oncotarget vol. 9,25 (2018): 17756-17769. doi: https://doi.org/10.18632/oncotarget.24879
Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A. Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget. 2018 Apr 03;9(25):17756-17769. doi: 10.18632/oncotarget.24879. eCollection 2018 Apr 03. PMID: 29707145; PMCID: PMC5915153.
Copy Download .nbib Format: NLM
Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.

Cancer medicine

Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, D'Hondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A.
PMID: 34057299
Cancer Med. 2021 Jul;10(13):4366-4374. doi: 10.1002/cam4.3976. Epub 2021 May 31.

BACKGROUND: While docetaxel/cisplatin/5-fluorouracil (DCF) outperforms CF in first-line gastric adenocarcinoma, toxicity remains an issue.METHODS: This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to fractionated weekly DCF (D 40 mg/mRESULTS: A total of 106 eligible patients were...

Cite
Deleporte A, Van den Eynde M, Forget F, et al. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. Cancer Med. 2021;10(13):4366-4374doi: 10.1002/cam4.3976.
Deleporte, A., Van den Eynde, M., Forget, F., Holbrechts, S., Delaunoit, T., Houbiers, G., Kalantari, H. R., Laurent, S., Vanderstraeten, E., De Man, M., Vergauwe, P., Clausse, M., Van Der Auwera, J., D'Hondt, L., Pierre, P., Ghillemijn, B., Covas, A., Paesmans, M., Ameye, L., Awada, A., Sclafani, F., & Hendlisz, A. (2021). Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. Cancer medicine, 10(13), 4366-4374. https://doi.org/10.1002/cam4.3976
Deleporte, Amélie, et al. "Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study." Cancer medicine vol. 10,13 (2021): 4366-4374. doi: https://doi.org/10.1002/cam4.3976
Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, D'Hondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. Cancer Med. 2021 Jul;10(13):4366-4374. doi: 10.1002/cam4.3976. Epub 2021 May 31. PMID: 34057299; PMCID: PMC8267119.
Copy Download .nbib Format: NLM
Structure and mineralization of the spearing mantis shrimp (Stomatopoda; Lysiosquillina maculata) body and spike cuticles.

Journal of structural biology

Delaunois Y, Smeets S, Malherbe C, Eppe G, Lecchini D, Ruffoni D, Compère P.
PMID: 34774752
J Struct Biol. 2021 Dec;213(4):107810. doi: 10.1016/j.jsb.2021.107810. Epub 2021 Nov 11.

Stomatopoda is a crustacean order including sophisticated predators called spearing and smashing mantis shrimps that are separated from the well-studied Eumalacotraca since the Devonian. The spearing mantis shrimp has developed a spiky dactyl capable of impaling fishes or crustaceans...

Cite
Delaunois Y, Smeets S, Malherbe C, et al. Structure and mineralization of the spearing mantis shrimp (Stomatopoda; Lysiosquillina maculata) body and spike cuticles. J Struct Biol. 2021;213(4):107810doi: 10.1016/j.jsb.2021.107810.
Delaunois, Y., Smeets, S., Malherbe, C., Eppe, G., Lecchini, D., Ruffoni, D., & Compère, P. (2021). Structure and mineralization of the spearing mantis shrimp (Stomatopoda; Lysiosquillina maculata) body and spike cuticles. Journal of structural biology, 213(4), 107810. https://doi.org/10.1016/j.jsb.2021.107810
Delaunois, Yann, et al. "Structure and mineralization of the spearing mantis shrimp (Stomatopoda; Lysiosquillina maculata) body and spike cuticles." Journal of structural biology vol. 213,4 (2021): 107810. doi: https://doi.org/10.1016/j.jsb.2021.107810
Delaunois Y, Smeets S, Malherbe C, Eppe G, Lecchini D, Ruffoni D, Compère P. Structure and mineralization of the spearing mantis shrimp (Stomatopoda; Lysiosquillina maculata) body and spike cuticles. J Struct Biol. 2021 Dec;213(4):107810. doi: 10.1016/j.jsb.2021.107810. Epub 2021 Nov 11. PMID: 34774752.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries